CD38 and COVID-19: COVID-19 patients show a substantial reduction in the numbers of peripheral CD4 and CD8 T cells, with the remaining cells exhibiting a hyperactivated status (CD38+ HLA-DR+) and are enriched for pro-inflammatory C-C chemokine receptor 6 (CCR6+) Th17 T cells.